...
机译:环膦酰胺在半任明奈多 - 地塞米松治疗期间复发/难治多骨髓瘤添加中的生化进展增加
Department of Cellular Biotechnologies and HaematologySapienza University of RomeRome Italy;
Institute of HaematologyS. Eugenio HospitalRome Italy;
Department of Cellular Biotechnologies and HaematologySapienza University of RomeRome Italy;
Department of HaematologyNuovo Regina Margherita HospitalRome Italy;
Department of HaematologyBelcolle HospitalViterbo Italy;
Department of HaematologyS. Camillo HospitalRome Italy;
Institute of HaematologyCatholic UniversityRome Italy;
Department of Cellular Biotechnologies and HaematologySapienza University of RomeLatina Italy;
Institute of HaematologyS. Eugenio HospitalRome Italy;
Department of Cellular Biotechnologies and HaematologySapienza University of RomeRome Italy;
biochemical relapse; cyclophosphamide; dexamethasone; lenalidomide; relapsed/refractory multiple myeloma;
机译:环膦酰胺在半任明奈多 - 地塞米松治疗期间复发/难治多骨髓瘤添加中的生化进展增加
机译:来那度胺和地塞米松治疗持续时间对来那度胺和地塞米松治疗的复发或难治性多发性骨髓瘤患者生存率的影响。
机译:多发复发/难治性骨髓瘤患者在来那度胺和地塞米松中添加环磷酰胺; I / II期研究。
机译:沙利度胺加上难治性/复发患者中的中间剂量地塞米松
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:环磷酰胺来那度胺硼替佐米和地塞米松治疗涉及整个肝脏的髓外复发和难治性多发性骨髓瘤的影像学特征
机译:MUK 8方案:环磷酰胺和地塞米松的随机期II试验与Ixazomib,复发或难治性多发性骨髓瘤(RRMM)患者与亚马亚度胺,Lenalidomide和蛋白酶体抑制剂进行处理后复发